Clinical Trials Logo

Hyperkinesis clinical trials

View clinical trials related to Hyperkinesis.

Filter by:

NCT ID: NCT01968512 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Neurobiological Aspects of the Attention Deficit Hyperactivity Disorder

NAADHD
Start date: October 2013
Phase: N/A
Study type: Interventional

Evaluating neurobiological disorder associated with Attention Deficit Hyperactivity Disorder (ADHD) and the contribution of transcranial direct current stimulation (tDCS) in the adaptation of inhibitory control.

NCT ID: NCT01967485 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Text Messaging Adherence to Stimulant Medication

Start date: January 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if an individualized text messaging intervention for the parents of children with Attention Deficit/Hyperactivity Disorder is effective in improving medication adherence and disease management.

NCT ID: NCT01962181 Not yet recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder

Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment

Start date: October 2013
Phase: N/A
Study type: Interventional

In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of Ritalin (methylphenidate) treatment.

NCT ID: NCT01943539 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Cognitive ADHD Videogame Exploratory Study

CAVES
Start date: September 2013
Phase: N/A
Study type: Interventional

A study in ADHD and neuro-typical children to assess EVO game play over 29 days.

NCT ID: NCT01940978 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Study of Combination Therapy in Children With ADHD

Start date: March 2014
Phase: Phase 4
Study type: Interventional

Lack of appetite and weight loss are a common side effect of ADHD therapy with amphetamines such as methylphenidate. Lack of sufficient food intake has been shown to have negative effects on weight and height as well as learning and memory. There is no current treatment to prevent this loss of appetite except discontinuation or reduction of the methylphenidate. Discontinuation or reduction of the drug can cause the return of ADHD symptoms. The purpose of this study is to compare the effects, good and/or bad, of two doses of a drug, cyproheptadine, vs placebo to find out if cyproheptadine prevents the appetite suppression associated with methylphenidate.

NCT ID: NCT01933880 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder (ADHD)

A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

Start date: December 2009
Phase: Phase 4
Study type: Interventional

The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder (ADHD).

NCT ID: NCT01918436 Recruiting - ADHD Clinical Trials

RCT, Proof of Concept Study of TEAMS (Training Executive, Attention and Motor Skills) Intervention Program

TEAMS
Start date: October 2012
Phase: N/A
Study type: Interventional

Background: TEAMS (Training Executive Attention and Motor Skills) is a non-pharmacological, neurocognitive intervention program targeted preschool children with ADHD developed by Professor Jeffrey Halperin, and his team from New York University. The uniqueness of this program lies in the concept, based on stimulating neurocognitive growth through focused physical activity and play (Halperin et al.; 2011, 2012, in press). Teams hypotheses: TEAMS is based on the notions that: 1. The behavioural manifestations of ADHD are the result of deficient neural networks that affect a wide array of neurocognitive and behavioural processes which are not necessarily identical in all children with the disorder. 2. Neurodevelopment is sensitive to and can be positively affected by appropriate environmental influences. 3. Effective environmental stimulation will be best achieved within a social context. 4. The engagement of the child in the core activities of the treatment must be intrinsically rewarding (i.e., fun) in order to facilitate compliance of the intervention. The initial research by Halperin et al. (2012)indicated significant improvement in ADHD severity from pre- to post-treatment, which also persisted 3 months later. Objective: The aim of this study is, through a randomized controlled trial (RCT), to validate the TEAMS treatment program in a clinical setting in Denmark. Method: Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program. The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand. The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups. In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.

NCT ID: NCT01912352 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder

Start date: May 2010
Phase: N/A
Study type: Interventional

The aims of the current study are to examine gene-environment interactions associated with norepinephrine (NE) system genes (ADRA2A, SLC6A2) in ADHD, and to evaluate whether genetic changes in norepinephrine pathway are associated with differences in functional connectivity of white matter fiber tracts, as measured by diffusion tensor imaging (DTI). Furthermore, this study aims to examine neurobiological markers, such as intermediate neuroimaging phenotypes or neuropsychological endophenotypes associated with the pathophysiology of ADHD. Through evaluating drug responses and side effects with the associated measures of clinical, neuropsychological and neuroimaging characteristics, investigators would like to investigate predictors of treatment response associated with NE system genes in ADHD.

NCT ID: NCT01886469 Completed - Clinical trials for Attention-Deficit Hyperactivity Disorder

A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.

NCT ID: NCT01876524 Completed - Schizophrenia Clinical Trials

tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients

tRND&SUDs
Start date: July 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to study the efficacy and security of noninvasive brain stimulation as a new approach for patients with Substance Use Disorders (SUDs) plus other psychiatric conditions like ADHD, Schizophrenia, Bipolar disorder, etc.